tiprankstipranks

Genmab Initiates Share Buy-Back Program to Optimize Capital Structure

Story Highlights
  • Genmab announced a share buy-back program to repurchase up to 2.2 million shares.
  • The buy-back program aims to reduce capital and fulfill commitments under the Restricted Stock Unit program.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

An announcement from Genmab ( (GMAB) ) is now available.

On March 31, 2025, Genmab A/S announced the initiation of a share buy-back program to repurchase up to 2.2 million shares, aiming to reduce capital and fulfill commitments under their Restricted Stock Unit program. The transactions executed between March 26 and March 28, 2025, resulted in Genmab holding 2,771,544 shares as treasury shares, representing 4.19% of the total share capital. This move is expected to impact Genmab’s financial structure and market positioning positively, aligning with the company’s strategic goals under the Safe Harbour Regulation.

More about Genmab

Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. The company has been pioneering next-generation antibody technology platforms for over 25 years, aiming to transform the lives of patients with cancer and other serious diseases through its proprietary pipeline, including bispecific T-cell engagers and antibody-drug conjugates.

YTD Price Performance: -5.24%

Average Trading Volume: 1,497,710

Technical Sentiment Signal: Buy

Current Market Cap: $12.58B

For a thorough assessment of GMAB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App